Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.
Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.
The FDA has granted fast track designation to APG-157 for the neoadjuvant treatment of head and neck cancer.
Naval G. Daver, MD, discusses efficacy and safety data from the first-in-human phase 1/2 study investigating DSP-5336 for relapsed or refractory acute leukemia.
The European Commission approved odronextamab for patients with relapsed/refractory FL or DLBCL who have received at least 2 prior lines of therapy.
When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.
BGB-16673 has received FDA fast track designation for relapsed or refractory CLL or SLL following 2 or more prior lines of therapy.
Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look…
Shipra Gandhi, MD, discusses the evolution of CDK4/6 inhibitors and ADCs across breast cancer subtypes.
An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with…
Triparna Sen, PhD, discusses findings from an interim analysis of the phase 2 IDeate-Lung01 trial in patients with extensive-stage small cell lung cancer.
